Trial Design
May 28
Valeria Paradies, Pieter C. Smits, et al.
The COMPARE STEMI ONE trial will assess the non-inferiority of 1-month DAPT followed by prasugrel monotherapy versus 12-month prasugrel-based DAPT, and the superiority of OCT-guided versus angiography-guided complete revascularisation in STEMI patients undergoing PCI.
Original Research
May 28
Giuseppe Gargiulo, Giovanni Esposito, et al.
This study assessed the pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention. Cangrelor provided effective platelet inhibition, but switching to oral P2Y12 inhibitors, especially clopidogrel, exposed patients to a period of high residual platelet reactivity.
Editorial
May 28
Francesco Franchi, Claudio Laudani
The study found that concomitant use of cangrelor and oral P2Y12 inhibitors may lead to drug-drug interactions and higher rates of high residual platelet reactivity, especially when switching from cangrelor to clopidogrel.
free
Expert Review
May 27
Sunny Goel, Gilbert H.L. Tang, et al.
This review explores various leaflet modification techniques, including BASILICA, ShortCut, and UNICORN, designed to mitigate the risk of coronary obstruction during transcatheter aortic valve implantation.
Original Research
May 27
Cristina Giannini, Anna Sonia Petronio, et al.
This registry assessed the incidence of long-term structural valve deterioration (SVD) beyond 5 years post-transcatheter aortic valve implantation (TAVI). The crude incidence of moderate/severe SVD was 9.5%, with predictors including intra-annular valve, small valve size, and paravalvular leak.
Research Correspondence
May 27
Ju Hyeon Kim, Seung‐Jung Park, et al.
OCT-guided percutaneous coronary intervention (PCI) showed comparable safety and effectiveness to IVUS-guided PCI in patients with and without acute coronary syndrome (ACS), despite increased procedural complexity and contrast use with OCT.
Viewpoint
May 27
Sanjay Kaul
Two transcatheter devices, EVOQUE and PASCAL, were recently approved by the FDA for improving health status in patients with severe tricuspid regurgitation. The approval has sparked a debate about the validity of unblinded trials with bias-prone outcomes.
Meet Cory, your AI Assistant!
Learn more
Enhance your reading experience and get deeper insights on complex topics.
Flashlight
May 26
Juan Manuel Muñoz Bravo, Bruno García del Blanco, et al.
The transcaval approach is a viable alternative to transfemoral access for TAVI procedures when the standard approach is not feasible, particularly in patients with complex anatomical features such as heavy calcium burden.
State-of-the-Art
May 26
Christian Pristipino, Lars Sondergaard, et al.
The study discusses the use of percutaneous PFO closure for the secondary prevention of PFO-related stroke in patients aged 18-60 years, and its potential use in other selected cases.
free
Original Research
May 26
Mauro Gitto, Roxana Mehran, et al.
In chronic coronary syndrome patients undergoing PCI, ticagrelor monotherapy after 3 months of DAPT had similar risks of ischaemic and bleeding events compared to standard ticagrelor-based DAPT, regardless of high ischaemic risk status.
Editorial
May 26
Hirotoshi Watanabe, Takeshi Kimura
The content discusses the management of chronic coronary syndrome, highlighting the need for lifestyle guidance, optimal drug treatment, and the decision to proceed with revascularization based on symptom status and patient preference.
free
May 23
Watch our video created to mark EuroIntervention’s 20 years, presented at EuroPCR 2025. Discover the visionaries behind the journal’s founding and those who have shaped it into what it is today.
Original Research
May 21
Youngwoo Jang, Woong Chol Kang, et al.
In ACS patients treated with drug-coated stents, a 1-month prasugrel-based DAPT strategy followed by prasugrel 5 mg monotherapy reduced net adverse clinical events by 49% compared to 12-month DAPT, primarily by lowering bleeding events without increasing ischaemic risk.
open access
Editorial
May 21
Thomas Cuisset, Guillaume Cayla
The 4D-ACS trial suggests that a shorter DAPT course followed by low-dose prasugrel monotherapy can reduce bleeding risk without compromising ischemic outcomes in ACS patients undergoing PCI.
free
Trending articles
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Management of cardiogenic shock
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Posterior pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: a systematic review and meta-analysis of 25 randomised controlled trials
Management of complications after valvular interventions
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Targeting inflammation in atherosclerosis: overview, strategy and directions
Leaflet modification techniques to mitigate coronary obstruction risk during transcatheter aortic valve implantation
Catheter-based techniques for pulmonary embolism treatment
Expert review
10.4244/EIJ-D-21-00690 • May 15, 2022
Moroni F et al
free
State-of-the-Art Review
10.4244/EIJ-D-20-01296 • Aug 27, 2021
Thiele H et al
free
State-of-the-Art
10.4244/EIJ-D-24-00386 • Feb 3, 2025
Ferro E et al
free
Meta-analysis
10.4244/EIJ-D-22-00948 • Jul 17, 2023
Abdelaziz A et al
free
State-of-the-Art
10.4244/EIJ-D-24-00066 • Apr 21, 2025
Bansal A et al
free
Clinical research
10.4244/EIJ-D-23-00344 • Sep 18, 2023
Sanchez-Luna JP et al
free
CLINICAL RESEARCH
10.4244/EIJ-D-17-00381 • Oct 11, 2017
Foin N et al
free
State-of-the-Art
10.4244/EIJ-D-23-00606 • Jan 1, 2024
Waksman R et al
free
Expert Review
10.4244/EIJ-D-24-00972 • May 16, 2025
Goel S et al
Expert Review
10.4244/EIJ-D-24-00535 • May 5, 2025
Costa F et al
